<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02678351</url>
  </required_header>
  <id_info>
    <org_study_id>PROS0075</org_study_id>
    <secondary_id>NCI-2016-00092</secondary_id>
    <secondary_id>35931</secondary_id>
    <secondary_id>PROS0075</secondary_id>
    <secondary_id>P30CA124435</secondary_id>
    <nct_id>NCT02678351</nct_id>
  </id_info>
  <brief_title>68Ga-PSMA PET/MRI in Finding Tumors in Patients With Intermediate or High-Risk Prostate Cancer Undergoing Surgery</brief_title>
  <official_title>68Ga-PSMA PET/MRI for Detection of Regional Nodal and Distant Metastases in Patients With Intermediate and High-Risk Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Andrei Iagaru</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II/III trial studies gallium 68 Ga (68Ga)-prostate-specific membrane antigen
      (PSMA) positron emission tomography/magnetic resonance imaging (PET/MRI) in finding tumors in
      patients with prostate cancer undergoing surgery that tend to spread quickly
      (intermediate-risk) or is likely to come back or spread (high-risk). Diagnostic procedures,
      such as PET/MRI, may help find and diagnose prostate cancer and find out how far the disease
      has spread. Radioactive drugs, such as gallium Ga 68-PSMA, binds to tumor cells that have
      specific receptors, and may allow doctors to see smaller tumors than the standard of care
      contrast-enhanced computed tomography (CT) or MRI scan.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. Evaluate 68Ga-PSMA PET/MRI for detection of regional nodal and distant metastases in
      patients with intermediate and high-risk prostate cancer scheduled to undergo prostatectomy
      with lymph node dissection.

      OUTLINE:

      Patients receive 68Ga-PSMA intravenously (IV). Patients then undergo PET/MRI after 45 minutes
      of administration of radiopharmaceutical injection.

      After completion of study, patients are followed up at 24-48 hours.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of patients who had true lesions</measure>
    <time_frame>Day 1</time_frame>
    <description>Point estimates and 95% confidence intervals will be calculated.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sensitivity of gallium Ga 68-PSMA PET/MRI</measure>
    <time_frame>Day 1</time_frame>
    <description>Sites of suspected metastatic disease will be graded on a three-point scale (0=negative, 1=equivocal, 2=positive), with statistical analysis performed with equivocal score of 1 graded as positive or negative on two separate analysis, for a more sensitive or specific visual read, respectively. Point estimates and 95% confidence intervals will be calculated.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Specificity of gallium Ga 68-PSMA PET/MRI</measure>
    <time_frame>Day 1</time_frame>
    <description>Sites of suspected metastatic disease will be graded on a three-point scale (0=negative, 1=equivocal, 2=positive), with statistical analysis performed with equivocal score of 1 graded as positive or negative on two separate analysis, for a more sensitive or specific visual read, respectively. Point estimates and 95% confidence intervals will be calculated.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Stage II Prostate Adenocarcinoma</condition>
  <condition>Stage III Prostate Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>Diagnostic (68Ga-PSMA PET/MRI)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive 68Ga-PSMA IV. Patients then undergo PET/MRI after 45 minutes of administration of radiopharmaceutical injection.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gallium Ga 68-PSMA</intervention_name>
    <description>Undergo gallium Ga 68-PSMA PET/MRI</description>
    <arm_group_label>Diagnostic (68Ga-PSMA PET/MRI)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Magnetic Resonance Imaging</intervention_name>
    <description>Undergo gallium Ga 68-PSMA PET/MRI</description>
    <arm_group_label>Diagnostic (68Ga-PSMA PET/MRI)</arm_group_label>
    <other_name>Magnetic Resonance Imaging Scan</other_name>
    <other_name>Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance</other_name>
    <other_name>MRI</other_name>
    <other_name>MRI Scan</other_name>
    <other_name>NMR Imaging</other_name>
    <other_name>NMRI</other_name>
    <other_name>Nuclear Magnetic Resonance Imaging</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Positron Emission Tomography</intervention_name>
    <description>Undergo gallium Ga 68-PSMA PET/MRI</description>
    <arm_group_label>Diagnostic (68Ga-PSMA PET/MRI)</arm_group_label>
    <other_name>Medical Imaging, Positron Emission Tomography</other_name>
    <other_name>PET</other_name>
    <other_name>PET SCAN</other_name>
    <other_name>Positron Emission Tomography Scan</other_name>
    <other_name>Positron-Emission Tomography</other_name>
    <other_name>proton magnetic resonance spectroscopic imaging</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Biopsy proven prostate adenocarcinoma

          -  Planned prostatectomy with lymph node dissection

          -  Intermediate to high-risk disease (as determined by elevated prostate-specific antigen
             [PSA] [PSA &gt; 10], T-stage [T2b or greater], Gleason score [Gleason score &gt; 6] or other
             risk factors)

          -  No evidence of metastatic disease on conventional imaging, including a negative bone
             scan for skeletal metastasis and/or negative cross section imaging (MR or CT)

          -  Able to provide written consent

          -  Karnofsky performance status of &gt;= 50 (Eastern Cooperative Oncology Group [ECOG]/World
             Health Organization [WHO] equivalent)

          -  No history of renal insufficiency

        Exclusion Criteria:

          -  Patients not capable of getting PET study due to weight, claustrophobia, or inability
             to lay still for the duration of the exam

          -  Neoadjuvant chemotherapy or radiation therapy prior to prostatectomy

          -  Androgen deprivation therapy prior to PET imaging

          -  Metallic implants
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrei Iagaru</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Risa Jiron</last_name>
    <phone>650-736-1598</phone>
    <email>rjiron@stanford.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Stanford University, School of Medicine</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Risa Jiron</last_name>
      <phone>650-736-1598</phone>
      <email>rjiron@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>Andrei Iagaru</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 2, 2016</study_first_submitted>
  <study_first_submitted_qc>February 4, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 9, 2016</study_first_posted>
  <last_update_submitted>August 31, 2017</last_update_submitted>
  <last_update_submitted_qc>August 31, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Andrei Iagaru</investigator_full_name>
    <investigator_title>Associate Professor of Radiology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

